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Nitrofurans belong to a group of synthetic broad spectrum antibacterial agents having
a nitrofuran ring. Nitrofurantoin [NFT, 1-{(5-nitro-2-furyl)methylideneamino}imidazoli-
dine-2,4-dione] is a nitro furan-derivative antibacterial agent, used in human and veteri-
nary medicine (1, 2). In humans, it is widely used to treat urinary tract infections. NFT is ef-
fective against common urinary tract pathogens, including Escherichia coli, Enterococci, Kleb-
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siella and Enterobacter. In therapeutic doses, it achieves urinary levels of > 200 µg mL–1. It is
generally bacteriostatic at low concentrations (5–10 µg mL–1) and bactericidal at higher
concentrations (3, 4). After oral administration, NFT is well absorbed from the gastro-
intestinal tract, with most of the absorption taking place in the proximal small intestine
(5). The drug is 20–60 % plasma protein bound and its bioavailability is affected by in-
gestion of food, particle size of the drug formulation and pH. It has been reported that
bioavailability of the drug increases from 87 (under fasting) to 94 % when taken with
food (6). The plasma half-life of NFT is ~ 30 min and is partially metabolized in the liver
to form amino-nitrofurantoin. After oral administration, 30–50 % NFT is excreted intact
in urine and ~ 1 % is excreted in urine as amino-nitrofurantoin (4).
Several analytical methods capable of determining NFT in biological matrices have
been reported based on stripping voltammetry (7, 8), high performance liquid chromato-
graphy (9–12) and LC-MS/MS (13, 14). These procedures have employed protein pre-
cipitation (PP) (12, 13), liquid-liquid extraction (LLE) (10, 14) or solid phase extraction
(SPE) (11) for quantitative and consistent recovery of NFT from human plasma. In all
chromatographic methods, the sensitivity (9–14), analysis time (11, 12) or plasma volume
for processing (11, 12) were the limiting factor. A selective HPLC-UV method has been
developed by Muth et al. (10) for determination of NFT in human plasma and urine. The
limit of quantification in plasma and urine was 10 and 380 ng mL–1, respectively, while
the chromatographic run time was 15 min. Adkison et al. (13) studied the effect of oral
NFT pharmacokinetics in healthy subjects by developing an LC-MS/MS method. The
plasma samples were prepared by protein precipitation and the calibration range was
20–10000 ng mL–1. Recently, Patil and co-workers (14) developed an LC-MS/MS method
with the limit of quantitation of 10.2 ng mL–1; however, the application was not reported.
In the present study, a sensitive, selective, robust and rapid LC-MS/MS method has
been proposed for the determination of NFT in human plasma. The method is extensi-




Reference standard material of nitrofurantoin (NFT, 99.9 %) and nitrofurazone (IS,
99.5 %) was procured from the USP Reference Standard (U.S. Pharmacopeial Conven-
tion, USA). HPLC grade methanol, acetonitrile, analytical grade reagent ammonium acetate
(98.0 %) and ammonia solution (30.0 %) were obtained from S.D. Fine Chemicals Ltd.
(India). HPLC grade dimethyl formamide (DMF) was obtained from Spectro Chem Pvt.
Ltd., (India). Strata-X polymeric reversed phase having 33 µm particle size and 800 m2
g–1 surface area (1 cm3, 30 mg) extraction cartridges were obtained from Phenomenex
(USA). Water used for LC-MS/MS was prepared using an Milli Q water purification sys-
tem from Millipore (India). Control buffered (K3EDTA) human plasma was procured from
the Clinical Department, Cliantha Research Limited (India), and was stored at –20 °C.
142
D. S. Patel et al.: Quantitation of nitrofurantoin in human plasma by liquid chromatography tandem mass spectrometry, Acta Pharm.
63 (2013) 141–158.
LC-MS/MS instrumentation and conditions
The liquid chromatography system from Shimadzu (Japan) consisted of a LC-10ADvp
pump, an autosampler (SIL-HTc) and an on-line degasser (DGU-14A). Chromatographic
column used was BDS Hypersil C18 (100 mm × 4.6 mm, 5.0 µm) from Thermo Scientific
(USA). For isocratic elution, the mobile phase consisted of acetonitrile/0.25 mmol L–1 am-
monium acetate (60:40, V/V) at a flow rate of 0.5 mL min–1. The auto sampler tempera-
ture was maintained at 4 °C and the injection volume was kept at 5.0 µL. Ionization and
detection of analyte and IS were performed on a triple quadrupole mass spectrometer,
API-3000 equipped with Turbo Ion spray®, from MDS SCIEX (Canada) operating in the
negative ion mode. Quantitation was done using the multiple reaction monitoring (MRM)
mode to monitor deprotonated precursor  product ion transition of m/z 237.0  151.8
for NFT and 197.0  123.9 for IS. All the LC and MS parameters were controlled by Analyst
software version 1.4.2.
For NFT and IS, the source dependant parameters maintained were gas 1 (nebulizer
gas) 68947 Pa, ion spray voltage –4500 V, turbo heater temperature 475 °C, entrance po-
tential –10 V, collision activation dissociation (CAD) 41368 Pa, curtain gas 41368 Pa. The
compound dependent parameters such as declustering potential, focusing potential, col-
lision energy and cell exit potential were optimized at –29, –160, –17 and –13.5 V for NFT
and –30, –175, –15 and –11 V for IS, respectively. Quadrupole 1 and 3 were maintained at
unit resolution, while the dwell time was set at 300 ms for both NFT and IS.
Preparation of standard stock and plasma samples
The NFT standard stock solution of 500 µg mL–1 was prepared by dissolving the re-
quired amount in DMF/deionized water (50:50, V/V). This was further diluted in the same
diluent to get an intermediate solution of 30 µg mL–1. Working solutions of NFT for spik-
ing plasma calibration and quality control samples were subsequently prepared using
the standard and intermediate stock solutions. The IS stock solution of 100 µg mL–1 was
prepared by dissolving the needed amount of nitrofurazone in DMF/deionized water
(50:50, V/V). IS working solution (1000 ng mL–1) was prepared from the stock solution in
deionized water. All the above solutions were stored at 4 °C until use. The calibration
standards (CS) and quality control (QC) samples [lower limit of quantitation quality con-
trol, LLOQ QC (5.00 ng mL–1); low quality control, LQC (15.0 ng mL–1); medium quality
control, MQC–2 (130.0 ng mL–1) and MQC-1 (600.0 ng mL–1); high quality control, HQC
(1125 ng mL–1); upper limit of quantitation quality control, ULOQ QC (1500 ng mL–1)]
were prepared by spiking blank plasma with the respective working solutions (5 % of
total plasma volume) in amber coloured ria vials (polypropylene tubes commonly used
in radio immunoassays). CSs were made at 5.00, 10.0, 25.0, 50.0, 100.0, 200.0, 400.0, 800.0,
1200 and 1500 ng mL–1 for NFT. Spiked plasma samples were stored at –20 °C for valida-
tion and subject sample analysis.
Sample preparation procedure
Prior to analysis, spiked plasma samples were thawed in a water bath and allowed
to equilibrate at room temperature. The samples were adequately vortexed using a vor-
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texer before pipetting. Aliquots of 100 µL plasma solution containing 5.0 µL NFT working
solution and 95 µL blank plasma were transferred into amber coloured ria vials, 10 µL of
deionized water (for CS and QC samples)/10 µL of 50 % DMF-deionized water solution
(for study samples) was added and vortexed to mix. Further, 150 µL IS working solution
(1000 ng mL–1) and 25 µL of 10 mmol L–1 ammonium acetate solution was added and
vortexed again. Prior to loading plasma samples, Strata-X cartridges were pre-washed
with 1.0 mL of methanol, followed by 1.0 mL of deionized water and centrifuged after
each step for 1.0 min at 1811×g. Plasma samples were then applied to these conditioned
cartridges and after centrifugation at 1811×g for 2.0 min, washing was done with 1.0 mL
of deionized water, followed by centrifugation for 1.0 min at 1811×g. Elution of samples
was carried out with 1.0 mL of acetonitrile/deionized water (60:40, V/V), followed by cen-
trifugation for 1.0 min at 1811×g. The eluent was transferred to amber coloured auto
injector vials and 5.0 µL was used for injection in LC-MS/MS, in partial loop mode.
Validation methodology
A thorough and complete method validation of NFT in human plasma was done
following the USFDA guidelines (15). Selectivity test was carried out in 13 different lots
of blank human plasma including haemolysed and lipemic plasma collected with
K3EDTA as an anticoagulant. From each of these 13 different lots, two replicates of 95 µL
each were spiked with 5.0 µL of the DMF/deionized water (50:50, V/V). In the first set,
the double blank plasma (without analyte and IS) was directly injected after extraction,
while the other set was spiked only with IS before extraction (total 26 samples). Further,
one system suitability sample (SSS) at CS-2 (10.0 ng mL–1) concentration and two repli-
cates of LLOQ concentration were prepared by spiking 95 µL blank human plasma with
5.0 µL of the respective working aqueous standards of NFT. The acceptance criterion re-
quires that at least 90 % of selectivity samples should be free from any interference at the
retention time of analyte and IS.
Interference due to commonly used medications in human volunteers was studied
for acetaminophen, aspirin, caffeine, cetrizine, chlorpheniramine maleate, ibuprofen and
pseudoephedrine. Their stock solutions (100 µg mL–1) were prepared by dissolving a re-
quisite amount in methanol. Further, working solutions (20.0 µg mL–1) were prepared in
DMF/deionized water (50:50, V/V), spiked in plasma (individually) along with NFT at
LQC and HQC levels. The samples were prepared in triplicate and analyzed using the
proposed extraction protocol. The final plasma concentration of these medications was
1000 ng mL–1. These sets were processed along with the freshly prepared calibration curve
standards and two sets (8 samples) of qualifying QC samples (HQC, MQC-1, MQC-2 and
LQC). As per the acceptance criteria, the accuracy should be within 85 and 115% (15).
A carryover experiment was performed to verify any carryover of analyte, which
may be reflected in subsequent runs. The design of the study comprised the following
sequence of injections, i.e., double blank plasma samples ® two samples of LLOQ ®
double blank plasma samples ® ULOQ sample ® double blank plasma samples to check
for any interference due to carryover.
The linearity of the method was determined by analysis of six calibration curves con-
taining ten non-zero concentrations. The area ratio response for NFT/IS obtained from mul-
tiple monitoring was used for regression analysis. Each calibration curve was analyzed
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individually using the least square weighted (1/x2) linear regression. The coefficient of
determination (R2) value > 0.99 was desirable for all the calibration curves. The lowest
standard on the calibration curve was accepted as the LLOQ, if the analyte response was
at least ten times higher than that of the drug free (blank) extracted plasma.
Intra-batch and inter-batch (on three consecutive validation days) accuracy and pre-
cision were evaluated at six QC levels (LLOQ QC, LQC, MQC-2, MQC-1, HQC and ULOQ
QC) in six replicates for NFT. The deviation (RSD, %) at each concentration level from
the nominal concentration was expected to be within ±15 %. Similarly, the mean accuracy
should not vary by ±15 % except for the LLOQ where it can be ±20 % of the nominal
concentration. Also, 2/3 quality control samples should meet the nominal concentration
criteria of ±15 %. Reinjection reproducibility was performed by re-injecting one entire
validation batch.
The relative recovery, matrix effect and process efficiency were evaluated as recom-
mended by Matuszewski et al. (16) at HQC, MQC-1, MQC-2 and LQC levels with six
replicates. Relative recovery (RE) was calculated by comparing the mean area response
of samples spiked before extraction to that of samples spiked after extraction at each QC
level. The recovery of IS was similarly estimated. Absolute matrix effect (ME) was asses-
sed by comparing the mean area response of samples spiked after extraction with the
mean area response of neat standard solutions prepared in elution solution. The overall
process efficiency (PE, %) was calculated as (ME × RE)/100. The relative matrix effect on
analyte quantification was also checked in eight different batches/lots of plasma, which
included six K3EDTA and one each of haemolysed and lipemic plasma. From each of
these batches, NFT samples at LQC and HQC levels were prepared in quadruplicate by
spiking NFT in extracted blank plasma and checked for RSD (%) and accuracy (%). De-
viation of the standards and QCs should not exceed ±15 %.
Matrix ion suppression-enhancement effects on the MRM (full given earlier) LC-MS/
MS sensitivity were evaluated by the post column analyte infusion experiment (17). A
standard solution containing NFT at the HQC level and 1000 ng mL–1 of IS in mobile
phase was infused post column via a 'T' connector into the mobile phase at 5.0 µL min–1
employing a Harvard infusion pump (Harvard Bioscience, USA). Aliquots of 5.0 µL of
extracted 1500 ng mL–1 sample and double blank plasma sample were then injected and
MRM LC-MS/MS chromatograms were acquired for NFT and IS. Any dip in the base-
line upon injection of double blank plasma would indicate ion suppression, while a peak
at the retention time of NFT and IS indicated ion enhancement.
All stability results were evaluated by measuring the area ratio response (NFT/IS)
of stability samples against freshly prepared comparison standards at LQC and HQC levels.
Stock solutions of NFT and IS were checked for short term stability at room temperature
and long term stability at 4 °C. The solutions were considered stable if the deviation from
the nominal value was within ±10.0 %. Bench top stability, processed sample stability at
room temperature and at refrigerated temperature (4 °C), freeze thaw stability and long
term stability at –20 °C were assessed at LQC and HQC levels using six replicates at each
level for NFT. To meet the acceptance criteria, the RSD (%) and accuracy (%) should be
within ±15 %. Also, at least 2/3 quality control samples should meet the nominal con-
centration criteria of ±15 %.
A dilution integrity experiment was performed with the aim to validate the dilution
test to be carried out on higher analyte concentrations (above ULOQ), which may be en-
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countered during real subject samples analysis. Dilution integrity experiment for NFT
was carried out using two solutions of different concentration, i.e., 7500 ng mL–1, which
is 5 times the ULOQ concentration (1500 ng mL–1) and 1125 ng mL–1 (HQC level). From
each of these solutions, six replicate samples were prepared at 1/10th dilution by taking
10 µL and diluting it with 90 µL screened blank human plasma. The precision and accu-
racy for these 1/10th diluted standard solutions were determined by robustness analyz-
ing the samples against freshly prepared calibration curve standards for NFT. Method
was evaluated on two precision and accuracy batches. The first batch was analyzed by
two analysts form different laboratories while the second batch was studied on two BDS
Hypersil C18.
Bioequivalence study and incurred sample reanalysis
The study plan was an open label, randomized, two period, two treatment, two
sequence, balanced, crossover, single dose evaluation of relative oral bioavailability of
the test (100 mg nitrofurantoin macro-crystalline capsules of a generic company) and a
reference (Macrodantin®, 100 mg nitrofurantoin macro-crystalline capsules from Procter
& Gamble Pharmaceuticals, USA) formulation in 36 healthy subjects under fed condi-
tions. All the subjects were informed of the aim and risk involved in the study and their
written consents were obtained. The inclusion criteria for volunteer selection was based
on the age (18–45 years), body mass index (between 18.5 and 24.9 kg m–2), general physi-
cal examination, electrocardiogram and laboratory tests like hematology, blood chemis-
try, urine examination and immunological tests. The exclusion criteria included allergic
responses to NFT, volunteers with a history of alcoholism, smokers and those having a
disease which may compromise the haematopoietic, gastrointestinal, renal, hepatic, car-
diovascular, respiratory, central nervous system, diabetes, psychosis or any other body
system. The work was subject to review and approved by an Independent Ethics Com-
mittee (IEC) of Cliantha Research Ltd., Ahmedabad, India. The subjects for the study
were fasted 10 h before administration of the drug formulation. They were given high fat
and high calory breakfast 30 min prior to taking the drug under investigation. Blood
samples were collected in vacutainers containing K3EDTA anticoagulant before (0 h) and
at 0.5, 1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 10, 12, 16 h after drug administra-
tion. Blood samples were centrifuged at 2415×g at 4 °C for 15 min; plasma was separated
and stored at –20 °C until use. The pharmacokinetic parameters of NFT were estimated
by a non-compartmental model using the WinNonlin software version 5.2.1 (Pharsight
Corporation, USA). An incurred sample re-analysis (ISR) was also conducted by compu-
terized random selection of subject samples, 10 % of total 1110 samples analyzed. The
selection criteria included samples which were near the cmax and the elimination phase
in the pharmacokinetic profile of the drug. The results obtained were compared with the
data obtained earlier for the same sample using the same procedure. The percent change
in the value should not be more than ±20 % (18).
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The extraction procedure, mass spectrometry and chromatographic conditions were
suitably optimized. During method development, electrospray ionization of NFT and nitro-
furazone was conducted in positive as well as negative ionization mode using 500 ng mL–1
tuning solution. However, the response was higher and consistent in the negative mode
under MRM with a signal-to-noise ratio > 1000 (with validated/finalized integration pa-
rameters) and a good linearity in regression curves. The analyte and IS gave predo-
minant singly charged deprotonated precursor [M–H]– ions at m/z of 237.0 and 197.0 for
NFT and IS, respectively, in Q1 full scan spectra. Further, fragmentation was initiated
using sufficient nitrogen for collision activation dissociation (CAD) and by applying
–17.0 V collision energy to break the precursor ions. The most abundant and consistent
ion found in the product ion mass spectra of NLF was at m/z 151.8, resulting from the
cleavage of the imidazolidine ring. The other characteristic fragment of NLF having ni-
trofuran substructure was observed at m/z 123.9, which can be attributed to the elimi-
nation of N2 from m/z 151.8, as shown in Fig. 1a. However, for nitrofurantoin, this frag-
ment (m/z 123.9) was the most abundant and reproducible product ion obtained at 15 V
collision energy in the Q3 spectra. The other product ions obtained for IS were at m/z
149.8 (due to elimination of nitro group from the precursor ion) and at m/z 106.9, as
shown in Fig. 1b. To attain an ideal Taylor cone and a better impact on spectral response,
an optimum potential of –4500 V was kept, which gave a stable signal. Fine tuning of
nebulizer gas (68947 Pa) and CAD gas was done to get a consistent and adequate res-
ponse. The ion source chamber temperature had little effect on the signal and was hence
maintained at 475 °C. A dwell time of 300 ms was adequate and no crosstalk was ob-
served between the MRMs of analytes.
During development, the chromatographic conditions were examined on BDS Hy-
persil C18, Hypurity C18 and Aquasil C18 (all 100 × 4.6 mm, 5.0 µm) columns to achieve
a short-run time, symmetric peak shapes, minimum matrix interference and solvent con-
sumption. To find the best mobile phase, different volume ratios (70:30, 60:40, 50:50 and
40:60, V/V) of methanol/water and acetonitrile/water combinations were tried as mobile
phases, along with formic acid (0.01–0.005 %) and ammonium acetate (0.1–5 mmol L–1).
In addition, the effect of the flow rate was also studied from 0.3 to 1.0 mL min–1, which
was also responsible for acceptable chromatographic peak shapes. Although acceptable
chromatography was achieved on all three columns with symmetric peak shape, the run
time was higher (> 5 min) on the Hypurity C18 and Aquasil C18 compared to the BDS
Hypersil C18 column. Moreover, the response was superior on the BDS Hypersil C18
column, especially at lower concentration (LLOQ and LQC) and hence it was selected
for the present work. A chromatographic run time of 3.5 min was possible using a mo-
bile phase consisting of acetonitrile/0.25 mmol L–1 ammonium acetate (60:40, V/V). A
flow rate of 0.5 mL min–1 was found most suitable for acceptable peak shapes and run
time. The reproducibility of retention time for the analyte was £ 0.6 % for 100 injections
on the same column. The maximum on-column loading (at ULOQ) of NFT per sample
injection volume was 0.75 ng. Due to the unavailability of deuterated analogue, a general
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IS was used to minimize analytical variation due to solvent evaporation and ionization
efficiency. Nitrofurazone, used as an IS in the present study is structurally similar to nitro-
furantoin, both possessing a 5-nitrofuran ring with substitution at the 2-position. Both
had similar chromatographic behavior and there was no effect of IS on analyte recovery,
sensitivity or ion suppression.
All three conventional extraction techniques, namely, protein precipitation (PP), li-
quid-liquid extraction (LLE) and solid phase extraction (SPE), were tested in the present
work for quantitative extraction of NFT from human plasma. PP was initially tried using
methanol, acetonitrile and perchloric acid as precipitating agents but the response was
inconsistent with some ion suppression at LLOQ and LQC levels. LLE was carried out in
ethyl acetate as reported earlier (10); however, the response found was inadequate at the
LLOQ level.
Solid phase extraction was tried on Strata-X polymeric reversed cartridges employ-
ing 100 mL plasma for processing in the presence of 10 mmol L–1 ammonium acetate.
Elution of samples with acetonitrile/deionized water (60:40, V/V) gave consistent and
quantitative recovery (>91 %) for NFT and IS at all QC levels.
System suitability, selectivity, interference and carryover check
During method validation, precision (RSD, %) was observed in the range of 0.1 to
0.6 % for the retention time and from 1.6 to 2.9 % for the area response of NFT and IS. All
plasma samples studied for selectivity were found free from any endogenous interference.
Figs. 2a-d demonstrate the selectivity results with chromatograms of double blank plasma
(without IS), blank plasma (with IS), peak response of NFT at LLOQ concentration and a
real subject sample chromatogram of NFT at 4.5 h after oral administration of 100 mg
capsule formulation. No interference was observed for commonly used medications like
acetaminophen, aspirin, caffeine, cetrizine, chlorpheniramine maleate, ibuprofen and
pseudoephedrine. Carryover evaluation was performed to ensure that it did not affect
the accuracy and precision of the proposed method. Almost negligible area (less than
0.5 % of LLOQ area) was observed in double blank plasma run after ULOQ, which sug-
gests no carryover of the analyte in subsequent runs.
Linearity, sensitivity, accuracy and precision
All six calibration curves were linear over the concentration range of 5.00–1500
ng mL–1 with the correlation coefficient R ³ 0.9984. A straight-line fit was made through
the data points by least square regression analysis to give the mean linear equation
y = (0.0049 ± 0.00011)g + (0.0034 ± 0.00013) where y is the peak area ratio of the analyte/
IS and g the concentration of the analyte. The accuracy and precision (RSD, %) observed
for the calibration curve standards ranged from 97.0 to 104.4 % and 1.3 to 8.1 %, respec-
tively. The lowest concentration (LLOQ) in the standard curve that can be measured
with acceptable accuracy and precision was 5.00 ng mL–1 at a signal-to-noise ratio (S/N) ³
36 and a limit of detection (LOD) of 0.25 ng mL–1.
The intra-batch and inter-batch precision and accuracy were established from vali-
dation runs performed at six QC levels (Table I). The intra-batch precision (RSD, %)
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ranged from 1.2 to 5.2 % and the accuracy was within 97.1 and 105.1 %. For the inter-
-batch experiments, the precision varied from 3.0 to 5.8 and the accuracy was within 94.3
and 100.6 %.
Recovery, matrix effect, matrix factor, ion suppression
The relative recovery, absolute matrix effect and process efficiency data for NFT are
presented in Table II. The relative recovery of the analyte is 'true recovery', which is
unaffected by the matrix as it is calculated by comparing the area ratio response
(analyte/IS) of extracted (spiked before extraction) and unextracted (spiked after
extraction) samples. The relative recovery obtained for NFT and IS was > 91 % at all QC
levels. Further, the relative matrix effect which compares the precision values (RSD, %)
between different lots (sources) of plasma (spiked after extraction) samples varied from
0.9 to 2.5 for NFT at the LQC and HQC levels. The accuracy values ranged from 98.7 to
103.1 % for both concentration levels. Results of the post-column analyte infusion chro-
matogram in Fig. 3 indicate no ion suppression or enhancement at the retention time of
NFT and IS. A minor suppression in the response was observed at 1.2 min; however, it
did not interfere with the quantitation. The average matrix factor value calculated as the
response of post spiked sample/response of neat solution (in elution solution) at the
LLOQ level was 0.98, which indicates a minor suppression of about 2 %.
Stability and dilution integrity
Stability experiments were performed to evaluate analyte stability in stock solutions
and in plasma samples under different conditions, simulating the same conditions that
occurred during study sample analysis. The stock solution of NFT was stable at room
temperature for 6 h and at 4 °C for 17 days. The intermediate stock solution of NFT in
DMF/deionized water (50:50, V/V) was stable at 4 °C for 14 days with a change of –0.1 %.
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LLOQ 5.00 5.05 101.0 2.2 4.76 95.2 5.0
LQC 15.0 14.9 99.3 3.6 14.7 98.0 4.3
MQC-2 130.0 129.1 99.3 3.0 127.5 98.1 3.0
MQC-1 600.0 582.4 97.1 5.2 591.4 98.6 5.8
HQC 1125.0 1194.1 106.1 2.4 1132.2 100.6 5.2
ULOQ 1500.0 1495.9 99.7 1.2 1414.1 94.3 5.5
a Mean of six replicate observations at each concentration.
b Mean of eighteen replicate observations over three different analytical runs.
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98963 (3.2) 96267 (2.5) 89764 (2.9) 97.3 (100.8)d 93.2 (93.6)d 90.7 (94.3)d
MQC-2
821457 (2.8) 801835 (0.7) 760287 (2.5) 97.6 (101.7)d 94.8 (92.7)d 92.5 (94.3)d
MQC-1
3858520 (1.8) 3696712 (1.8) 3383058 (2.6) 95.8 (102.5)d 91.5 (92.2)d 87.7 (94.5)d
HQC
7481403 (2.0) 7183531 (1.5) 6685993 (2.8) 96.0 (100.2)d 93.1 (91.4)d 89.4 (91.6)d
A – Mean area response of six replicate samples prepared in mobile phase (neat samples).
B – Mean area response of six replicate samples prepared by spiking in extracted blank plasma.
C – Mean area response of six replicate samples prepared by spiking before extraction.
a B/A × 100
b C/B × 100
c C/A × 100
d In parentheses values for internal standard, nitrofurazone.
Fig. 3. Representative post column analyte infusion MRM LC-MS/MS overlaid chromatograms for
nitrofurantoin and nitrofurazone: a) exact ion current (XIC) chromatogram of nitrofurantoin (m/z
237.0 ® 151.8), b) XIC of nitrofurazone (IS, m/z 197.0 ® 123.9).
a)
b)
NFT was found stable in control plasma at room temperature up to 24 h and for six freeze
and thaw cycles. The analyte in extracted plasma samples (processed samples) in acetoni-
trile/deionized water (60:40, V/V) was stable for 98 h under refrigerated conditions (4
°C) and for 98 h at room temperature. Spiked plasma samples of NFT stored at –20 °C
for long term stability were found stable for a minimum period of 95 days. Values for the
percent change for all stability experiments are compiled in Table III.
The precision values for dilution integrity of 1/10 of 5 times ULOQ (750.0 ng mL–1)
and 1/10 of HQC (112.5 ng mL–1) concentration were 1.3 and 0.9 %, while accuracy results
were within 94.8 and 97.6 %, respectively, which is within the acceptance limit of 15 % for
precision and 85 to 115 % for accuracy. For method robustness the precision and accuracy
values for two different columns ranged from 3.0 to 3.8 % and 96.5 to 101.2 %, respective-
ly, at all six QC levels. For the experiment with different analysts, the results for precision
and accuracy were within 2.2 to 3.3 % and 97.2 to 102.5 %, respectively, at these levels.
Application of the method to human subjects and incurred sample reanalysis
The validated method was applied for a bioequivalence study of NFT in 36 healthy
male subjects, who received 100 mg test and reference formulations of NFT under fed con-
ditions. The mean pharmacokinetic profile for the treatment is presented in Fig. 4. The
method was sensitive enough to monitor their plasma concentration up to 16 h. In all,
1968 samples including calibration, QC and volunteer samples were run and analyzed.
The precision and accuracy for calibration and QC samples were well within the accept-
able limits. The mean pharmacokinetic parameters obtained for the test and reference for-
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Table III. Stability results for nitrofurantoin under different conditions








LQC 13.71 ± 0.72 –8.7





(4 °C, 98 h)
LQC 13.70 ± 0.34 –8.7






LQC 14.33 ± 0.15 –4.6
HQC 1083.23 ± 20.53 –3.7
Freeze and thaw
stability
After 6th cycle at
–20 °C
LQC 14.13 ± 0.21 –6.0




LQC 15.51 ± 0.63 3.3
HQC 1038.42 ± 27.23 –7.7
LQC – low quality control (15 ng mL–1).
HQC – high quality control (1125 ng mL–1).
a Mean ± SD, n = 6 (replicates at each level).
b Values within the acceptance criteria of ±15 % as per US FDA guidelines (15).
mulation are presented in Table IV. The cmax and tmax values obtained under fed condi-
tions were slightly higher and lower, respectively, compared to the reported work (13). This
may be due to genetic difference, race, age, gender (body size and muscle mass), type of
food, etc., which may result in pharmacokinetic differences. However, their AUC0-inf value
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Fig. 4. Mean plasma concentration-time profile of nitrofurantoin after oral administration of a test
(100 mg, nitrofurantoin capsules from a generic company) and a reference (100 mg, nitrofurantoin
capsules from Procter & Gamble Pharmaceuticals, USA) formulation to 36 healthy subjects under
fed condition. Mean ± SD, n = 36.
Table IV. Mean pharmacokinetic parameters after administration of a 100-mg nitrofurantoin capsule
formulation administrated orally to 36 healthy subjects under fed conditions.
Parameter Reference Test
Mean ± SDa Mean ± SDa
cmax (ng mL–1) 513.4 ± 49.0 506.5 ± 37.2
tmax (h) 4.50 ± 1.04 4.71 ± 1.05
t1/2 (h) 1.66 ± 0.31 1.55 ± 0.32
AUC0-16h (h ng mL–1) 2321.58 ± 477.19 2401.65 ± 405.34
AUC0-inf (h ng mL–1) 2622.29 ± 534.61 2563.89 ± 425.28
kel (h–1) 0.418 ± 0.028 0.447 ± 0.019
cmax – maximum plasma concentration.
tmax – time point of maximum plasma concentration.
t1/2 – half-life of drug elimination during the terminal phase.
AUC0-t – area under the plasma concentration-time curve from zero hour to 16 h.
AUC0-inf – area under the plasma concentration-time curve from zero hour to infinity.
kel – elimination rate constant.
a n = 36
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was comparable with the present work. The ratio of mean log-transformed data (test/re-
ference formulation) for cmax, AUC0-t and AUC0-inf (98.7, 103.5 and 97.8 %, respectively)
and their 90 % confidence intervals (93.1–103.1, 98.0–108.1 and 92.6–102.5 %, respectively)
were all within the defined bioequivalence range. These observations confirm the bioequi-
valence of the test sample with the reference product in terms of rate and extent of ab-
sorption. Out of 111 reanalyzed incurred samples, 83 samples showed a change for assay
reproducibility within ±5 % while the remaining 28 samples were within ±5.0 to ±10 %.
This authenticates the reproducibility of the proposed method.
Comparison with reported methods
The method presented has a higher sensitivity compared to previously reported meth-
ods (9–14) developed for NFT in plasma. The organic solvent consumption per sample
analysis (extraction and chromatography) was only 2.7 mL, which is considerably lower
compared to these methods. Ion suppression/enhancement was checked by the post-co-
lumn infusion technique and the quantitative assessment of matrix effects was evaluat-
ed by calculating the absolute and differential matrix effect, which was not reported in
previous studies. Similarly, incurred sample reanalysis, which has now become manda-
tory for clinical and non-clinical studies, has proven the reproducibility in the measure-
ment of subject samples for the first time for NFT. Table V gives a comparison of the
salient features of chromatographic methods developed for NFT in plasma.
CONCLUSIONS
The objective of the present work was to develop and fully validate a simple, selec-
tive and sensitive method for NFT in human plasma by the turbo ion spray LC-MS/MS
for routine sample analysis. The solid phase extraction procedure employed in the pre-
sent work gave consistent and quantitative recoveries of NFT at all QC levels. The
method requires only 100 µL human plasma for extraction and demonstrates excellent
performance in terms of robustness and efficiency (3.5 min per sample). The dynamic
linear range was validated from 5.0–1500 ng mL–1. The maximum on-column loading at
ULOQ was 0.75 ng for a 5.0 µL injection volume, which helps in maintaining the effi-
ciency and lifetime of the column. Moreover, the limit of quantification is low enough to
monitor at least five half-lives of NFT concentration with good intra- and inter-assay re-
producibility for quality control. The method was selective in the presence of medica-
tions commonly used by human volunteers. Ion suppression/enhancement was studied
by the post column infusion of analyte and post extraction spiking technique. The pro-
posed method has been successfully applied to a bioequivalence study of 100 mg nitro-
furantoin capsule formulation in 36 healthy males under fed condition. Reliability of the
measurement of study samples is shown by incurred sample reanalysis.
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